Cognition Therapeutics Says Study of Drug to Treat Lewy Body Dementia Meets Primary Endpoint; Shares Jump

MT Newswires Live12-18

Cognition Therapeutics (CGTX) said Wednesday that a phase 2 study of CT1812 to treat patients with Lewy body dementia met its primary endpoint of safety and tolerability.

The drug produced "strong therapeutic responses across behavioral, functional, cognitive and movement measures" in patients who received the treatment for six months, compared to placebo.

The results showed a 82% slowing in neuropsychiatric inventory decline and a 91% reduction in attention fluctuations, while reducing anxiety, hallucinations and delusions, Cognition said.

The company said it expects to review the results with the Food and Drug Administration in an end-of-phase 2 meeting and to advance CT1812 into late-stage trials.

Cognition Therapeutics shares were 135% higher in recent premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492918633?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 21:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492918633","market":"hk","top_or_hot":-1,"title":"Cognition Therapeutics Says Study of Drug to Treat Lewy Body Dementia Meets Primary Endpoint; Shares Jump","media":"MT Newswires Live","content":"<html><body><p> Cognition <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CGTX) said Wednesday that a phase 2 study of CT1812 to treat patients with Lewy body dementia met its primary endpoint of safety and tolerability.</p><p>The drug produced \"strong therapeutic responses across behavioral, functional, cognitive and movement measures\" in patients who received the treatment for six months, compared to placebo.</p><p>The results showed a 82% slowing in neuropsychiatric inventory decline and a 91% reduction in attention fluctuations, while reducing anxiety, hallucinations and delusions, Cognition said.</p><p>The company said it expects to review the results with the Food and Drug Administration in an end-of-phase 2 meeting and to advance CT1812 into late-stage trials.</p><p>Cognition Therapeutics shares were 135% higher in recent premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cognition Therapeutics Says Study of Drug to Treat Lewy Body Dementia Meets Primary Endpoint; Shares Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCognition Therapeutics Says Study of Drug to Treat Lewy Body Dementia Meets Primary Endpoint; Shares Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 21:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cognition Therapeutics (CGTX) said Wednesday that a phase 2 study of CT1812 to treat patients with Lewy body dementia met its primary endpoint of safety and tolerability.The drug produced \"strong ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492918633","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492918633","pubTimestamp":1734529761,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cognition Therapeutics  said Wednesday that a phase 2 study of CT1812 to treat patients with Lewy body dementia met its primary endpoint of safety and tolerability.The drug produced \"strong therapeutic responses across behavioral, functional, cognitive and movement measures\" in patients who received the treatment for six months, compared to placebo.The results showed a 82% slowing in neuropsychiatric inventory decline and a 91% reduction in attention fluctuations, while reducing anxiety, hallucinations and delusions, Cognition said.The company said it expects to review the results with the Food and Drug Administration in an end-of-phase 2 meeting and to advance CT1812 into late-stage trials.Cognition Therapeutics shares were 135% higher in recent premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4007":"制药","CGTX":"Cognition Therapeutics, Inc","BK4139":"生物科技"},"translate_title":"Cognition Therapeutics表示，治疗路易体痴呆的药物研究达到了主要终点；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGTX":1,"LENZ":1},"content_text":"Cognition Therapeutics (CGTX) said Wednesday that a phase 2 study of CT1812 to treat patients with Lewy body dementia met its primary endpoint of safety and tolerability.The drug produced \"strong therapeutic responses across behavioral, functional, cognitive and movement measures\" in patients who received the treatment for six months, compared to placebo.The results showed a 82% slowing in neuropsychiatric inventory decline and a 91% reduction in attention fluctuations, while reducing anxiety, hallucinations and delusions, Cognition said.The company said it expects to review the results with the Food and Drug Administration in an end-of-phase 2 meeting and to advance CT1812 into late-stage trials.Cognition Therapeutics shares were 135% higher in recent premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492918633"}